HeartSciences (NASDAQ:HSCS) Stock Rating Upgraded by Wall Street Zen

HeartSciences (NASDAQ:HSCS) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday, Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, HeartSciences presently has an average rating of “Hold” and an average price target of $8.00.

HeartSciences Price Performance

Shares of HSCS stock opened at $4.68 on Friday. The stock’s 50-day moving average is $2.85 and its 200 day moving average is $2.45. HeartSciences has a 1-year low of $1.63 and a 1-year high of $5.25. The company has a market cap of $22.46 million, a P/E ratio of -1.45 and a beta of 1.85.

HeartSciences (NASDAQ:HSCS) last announced its earnings results on Monday, September 14th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14). The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.10 million. On average, analysts anticipate that HeartSciences will post -2.99 EPS for the current year.

HeartSciences Company Profile

HeartSciences, Inc is a medical technology company focused on improving the detection and management of cardiovascular disease. The company develops electrocardiography (ECG) technologies intended to provide clinicians with additional information about cardiac function using a test that is widely available in healthcare settings.

Its principal technology is the MyoVista wavECG system, which applies proprietary signal-processing methods, including wavelet analysis, to standard 12-lead ECG data.